GlassScriptPhysician profile
Nancy D Hart
NPI 1073536603
$4,828.75
in general payments reported to CMS, 2019-2025
19 companies · $1,806 in 2025
The $1,806 reported for 2025 was more than what 91% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $151 · 2022: $393 · 2023: $1,058 · 2024: $1,422 · 2025: $1,806.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,285.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,285.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $665.70 | 2021-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $659.06 | 2022-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Abbvie INC. | $497.21 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $468.61 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $424.25 | 2022-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Alkermes, INC. | $352.67 | 2021-2025 | Aristada, Lybalvi |
| Supernus Pharmaceuticals, INC. | $317.97 | 2024-2025 | Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $298.45 | 2022-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $221.13 | 2024-2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $218.20 | 2023-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $182.85 | 2024-2025 | Cobenfy |
| Indivior INC. | $132.39 | 2022-2025 | Sublocade |
| Corium, LLC | $112.98 | 2024-2025 | Azstarys |
| Axsome Therapeutics, INC. | $112.95 | 2023-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $63.34 | 2022-2024 | Trintellix |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $34.96 | 2025 | Loreev Xr |
| Ironshore Pharmaceuticals INC. | $26.27 | 2022-2023 | Jornay Pm |
| Acadia Pharmaceuticals INC | $25.50 | 2025 | Daybue |
| Tris Pharma INC | $14.26 | 2025 | Dyanavel Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Hart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.